Whole-body [$^{18}$F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation

L. Kurch, R. Kluge, O. Sabri, L. Fischer, S. Wendt, H. Graf Einsiedel, S. Starke, J.-S. Kühl, H. Christiansen, F. W. Hirsch, I. Sorge and C. Roth

Abstract

Aim: In 2015, the revised International Pediatric Non-Hodgkin Lymphoma Staging System was published. It mentions [$^{18}$F]-FDG-PET/MRI as the latest method to perform whole-body imaging. However, supporting data are pending. Our aim was to investigate the performance of whole-body [$^{18}$F]-FDG-PET/MRI in pediatric non-Hodgkin lymphoma patients by using a limited number of MRI sequences.

Materials and methods: Ten pediatric patients with histologically proven non-Hodgkin lymphoma underwent whole-body [$^{18}$F]-FDG-PET/MRI at staging. The retrospective analysis included three steps: First, [$^{18}$F]-FDG-PET and MR scans were evaluated separately by a nuclear medicine physician and a pediatric radiologist. Nineteen nodal and two extranodal regions as well as six organs were checked for involvement. Second, discrepant findings were reviewed together in order to reach consensus. Third, [$^{18}$F]-FDG-PET/MRI findings were correlated with the results of other clinical investigations.

Results: Of the 190 lymph node regions evaluated, four were rated controversial. Consensus was reached by considering metabolic, functional and morphologic information combined. Concordantly, [$^{18}$F]-FDG-PET and MRI detected Waldeyer’s ring involvement in two patients whose Waldeyer’s ring was negative on clinical assessment. In four patients MRI showed pleural effusion. However, in only two of them an increased glucose metabolism as a reliable sign of pleural involvement was detectable. In six patients [$^{18}$F]-FDG-PET and MRI detected skeletal lesions although bone marrow biopsy was positive in only one of them.

Conclusion: Despite the small number of cases evaluated, whole-body [$^{18}$F]-FDG-PET turned out to be a valuable tool for staging of pediatric non-Hodgkin lymphoma.

Keywords: [$^{18}$F]-FDG-PET/MRI, Hybrid imaging, Pediatric non-Hodgkin lymphoma, Pediatric oncology

Introduction

Lymphoma is the third most common malignancy in children and adolescents. About 60% account for non-Hodgkin lymphoma (NHL) and 40% for Hodgkin lymphoma (HL). In the past 40 years, major advances were achieved in the fields of cytotoxic drug development, radiation oncology, pathology and imaging technologies. Each of them contributed to a more individualized treatment.

The role of the latest whole-body imaging technologies, [$^{18}$F]-FDG-PET/CT and [$^{18}$F]-FDG-PET/MRI, has been studied, but much more extensively in pediatric HL than in pediatric NHL [1]. Yet, according to the PubMed database, to date there is no publication available which exclusively addresses the application of simultaneous
[18F]-FDG-PET/MRI in pediatric NHL (last PubMed query: April, 14, 2021).

In 2015, the revised International Pediatric non-Hodgkin Lymphoma Staging System (IPNHLSS) was published and since then replaces the St. Jude classification by Murphy from the 1980s [2]. The main publication on the revised IPNHLSS also considers advances in imaging technologies and points out the efficiency and potency of hybrid imaging such as [18F]-FDG-PET/CT and [18F]-FDG-PET/MRI [2]. [18F]-FDG-PET/MRI seems to be especially promising since it can depict metabolic (i.e., the degree of glucose turnover), functional (i.e., the diffusion movement of water molecules) and morphological properties of tumor lesions at the same time. Considering all three aspects combined could be substantial for accurate characterization of lesions and may reduce the deficiencies of each modality when used separately. Furthermore, radiation exposure can be saved when replacing CT imaging by MRI.

However, whole-body imaging with [18F]-FDG-PET/MRI represents a compromise between the acquisition of all potentially possible MR sequences and a reasonable overall scan duration [3]. The overall scan duration is the determining factor with regard to compliance of young patients. It should not exceed 60 min [3].

The aim of this retrospective single-center evaluation was to investigate the performance of whole-body [18F]-FDG-PET/MRI in pediatric NHL patients by using a limited number of MRI sequences.

Patients, materials and methods

Patients

Between April 2012 and November 2019 ten pediatric NHL patients received whole-body [18F]-FDG-PET/MRI for initial staging.

Written informed consent was obtained from all patients and/or their legal guardians for scientific evaluation of imaging data before inclusion into this retrospective evaluation.

The data evaluation was approved by the local Ethics Committee.

Patient data and investigations beyond [18F]-FDG-PET/MRI

For each patient, age, sex, histology, the presence of B symptoms and the level of lactate dehydrogenase (LDH) were documented. Wherever available, the results of ear, nose and throat (ENT) examination, lumbar puncture, bone marrow (BM) biopsy, thoracentesis as well as computed tomography (CT) of the chest and ultrasound of the abdomen were considered for correlation with the [18F]-FDG-PET/MRI images.

[18F]-FDG-PET/MRI imaging

Images were acquired on a 3 Tesla Biograph mMR (Siemens, Erlangen, Germany) which had been installed in 2011.

Prior to the [18F]-FDG injection all patients fasted for at least 6 h.

To avoid activation of brown adipose tissue all patients were warmed for at least 30 min before [18F]-FDG injection. In addition, the unselective beta-blocker propranolol (1 mg/kg, maximum dose = 40 mg) was administered approximately one hour before tracer injection.

The upper limit of [18F]-FDG activity to be administered was determined by the EANM dosage calculator [4]. Dosing reduction ranged from 24 to 67% of the recommended upper activity limit in nine patients (Table 1).

In one patient with marginal overweight the administered activity reached the recommended upper limit (Table 1).

Time interval between radiotracer injection and start of the scan ranged from 45 to 135 min for nine patients (Table 1). The variation in injection to imaging time is mainly due to unexpected demand on the scanner throughout daily routine. In one patient the interval was 180 min due to temporary scanner dysfunction (Table 1).

One of the ten patients needed sedation for [18F]-FDG-PET/MRI acquisition (Table 1).

[18F]-FDG attenuation correction was carried out per section with a MR Dixon sequence as described by Hirsch et al. [3].

Water-sensitive fast inversion recovery sequences (T2-TIRM) with 5 mm in coronal and 4.5 mm in transversal plane were acquired to provide anatomical coverage of the entire body. This was limited to a maximum length of 160 cm (seven stacks with overlap of 30 cm length each). Taller children and adolescents underwent a second scan covering the legs after repositioning.

Respiratory triggering with a belt system was used for image acquisition of the thoracic and upper abdominal region in order to obtain improved image quality and to minimize breathing artifacts.

To reduce artifacts through excessive peristalsis all patients received butylscopolamine approximately 10–15 min before acquisition of the abdominal region was performed (0.3 mg/kg, maximum dose = 20 mg).

Additionally, diffusion-weighted images (DWI) with a slice thickness of 6 mm were acquired if patient compliance was sufficient. This was the case in eight of the ten patients (Table 1). One patient, however, refused an additional DWI whereas a second patient was unable to lie still during DWI acquisition resulting in severe movement artifacts. DWI allowed for calculation of the apparent diffusion coefficient (ADC). ADC cutoff values
| Pat | Age  | Histology     | ENT<sub>clin</sub> | TC  | LP  | BMB | US abdomen | <sup>18</sup>F-FDG<sub>adm</sub> | <sup>18</sup>F-FDG<sub>rec</sub> | Δ<sub>INJECT/SCAN</sub> | Sedation | Images performed | Result of PET/MR scan | Figure |
|-----|------|---------------|-------------------|-----|-----|-----|------------|-----------------|-----------------|-------------------|----------|-------------------|----------------------|--------|
| 1   | 15 years | Burkitt | n.d            | n.d | n.d | n.d | Splenomegaly, otherwise US - | 212 MBq (−39%) | 348 MBq | 90 min | No | WB PET; WB MRT2-TIRM<sub>cor</sub> + trans; WB DWI<sub>trans</sub> | Nodular lymphoma involvement on both sides of the diaphragm | |
| 2   | 16 years | DLBCL<sub>oss</sub> | n.d | n.d | n.d | n.d | | 276 MBq (−24%) | 363 MBq | 90 min | No | WB PET; WB MRT2-TIRM<sub>cor</sub> + trans; WB DWI<sub>trans</sub> | Nodular lymphoma involvement on both sides of the diaphragm, extensive involvement of the left pelvic bones with cortical bone destruction and infiltration of adjacent muscles | Figure 8i–l |
| 3   | 6 years | DLBCL | n.d | n.d | n.d | n.d | n.d | 64 MBq (−49%) | 126 MBq | 135 min | Yes | WB PET; WB MRT2-TIRM<sub>cor</sub> + trans; WB DWI<sub>trans</sub> | Nodular lymphoma involvement on both sides of the diaphragm | Figures 1, 3 |
| 4   | 7 years | DLBCL | n.d | n.d | n.d | n.d | n.d | 91 MBq (−39%) | 148 MBq | 110 min | No | WB PET; WB MRT2-TIRM<sub>cor</sub> + trans; WB DWI<sub>trans</sub> | Nodular lymphoma involvement on both sides of the diaphragm | |
| 5   | 10 years | DLBCL<sub>oss</sub> | n.d | n.d | n.d | n.d | n.d | 126 MBq (−45%) | 229 MBq | 180 min | No | WB PET; WB MRT2-TIRM<sub>cor</sub> + trans; WB DWI<sub>trans</sub> | Long segmental lymphoma involvement of the left femur with cortical bone destruction and infiltration of adjacent muscles | |
| 6   | 10 years | T-cell lymphoma | n.d | n.d | n.d | Bilateral renal involvement, otherwise US - | 278 MBq (−0%) | 277 MBq | 110 min | No | WB PET; WB MRT2-TIRM<sub>cor</sub> + trans; WB DWI<sub>trans</sub> | Nodular lymphoma involvement on both sides of the diaphragm including Waldeyer's ring. In addition bilateral kidney and skeletal involvement (right femur) | Figures 6, 7 |
### Table 1 (continued)

![Table with data](https://example.com/table1-continued.png)

| Pat | Age  | Histology  | ENTclin | TC | LP | BMB | USabdomen | $^{18}$F-FDG$_{adm}$ | $^{18}$F-FDG$_{recom}$ | Δ$_{inj}$/scan | Sedation | Images performed | Result of PET/MR scan | Figure  |
|-----|------|------------|---------|----|----|-----|------------|----------------|----------------|-------------|----------|----------------|------------------|---------|
| 7   | 14 years | Burkitt | − | n.d | − | − | − | 162 MBq (−45%) | 292 MBq | 45 min | No | WB PET; WB MRT T2-TIRM$_{cor}$ | Nodular lymphoma involvement above diaphragm including Waldeyer's ring. Moreover, focal skeletal involvement. | Figures 4, 7, 8a–h |
| 8   | 15 years | T-cell lymphoma | + | n.d | − | − | − | 67 MBq (−67%) | 200 MBq | 70 min | No | WB PET; WB MRT T2-TIRM$_{cor}$ | Nodular lymphoma involvement above diaphragm and left pleura, extended bilateral and focal skeletal involvement (left femur). Waldeyer's ring involvement most unlikely | Figure 2 |
| 9   | 4 years | T-cell lymphoma | + | + | − | − | − | 45 MBq (−51%) | 92 MBq | 70 min | No | WB PET; WB MRT T2-TIRM$_{cor}$ | Nodular lymphoma involvement above diaphragm and left-sided pleural involvement. Waldeyer's ring involvement most unlikely | Figure 5 |
| 10  | 17 years | DLBCL | − | n.d | − | − | − | 239 MBq (−31%) | 348 MBq | 80 min | No | WB PET; WB MRT T2-TIRM$_{cor}$ | Nodular lymphoma involvement above diaphragm | |

*BMB, Result of Bone Marrow Biopsy; Cor, coronal; DLBCL$_{os}$, Primary Osseous Large B-cell Lymphoma; ENTclin, Result of clinical ENT investigation; $^{18}$F-FDG$_{adm}$, Administered $^{18}$F-FDG activity; LP, Result of Lumbar Puncture; min, minutes; n.e., not evaluable; TC, Thoracentesis; Trans, transversal; US$_{abdomen}$, Result of abdominal ultrasound; y, years; Δ$_{inj}$/scan, Time interval from tracer injection to scan start; +, positive for lymphoma; −, negative for lymphoma; Burkitt, Burkitt Lymphoma; DLBCL, Diffuse Large B-cell Lymphoma; DWI, Diffusion Weighted Imaging; f, female; $^{18}$F-FDG$_{recom}$, Recommended $^{18}$F-FDG activity; m, male; n.d., not done; Pat, Patient number; T-cell LL, T-cell Lymphoma; T2-TIRM, T2 weighted Turbo-Inversion Recovery Magnitude; WB, wholebody*
(B-values) at or less than 800 × 10⁻⁶ mm²/s were regarded as diffusion restriction.

Altogether, the acquisition with its detailed parameters was in accordance with recommendations by Hirsch et al. [3].

[¹⁸F]-FDG-PET/MRI data analysis

[¹⁸F]-FDG-PET/MRI datasets were retrospectively analyzed by an experienced pediatric radiologist (CR) and an experienced nuclear medicine physician (LK), both having more than 10 years’ experience in their respective field. Nineteen lymph node regions, adapted to [5], two extranodal regions [Waldeyer’s ring (WR), pleura] as well as six organs [central nervous system (CNS), lungs, liver, spleen, kidneys and skeleton) were defined for evaluation.

First, [¹⁸F]-FDG-PET images were evaluated by the nuclear medicine physician and MR images (T2-TIRM coronal and transversal) by the pediatric radiologist. The nuclear medicine physician focused on the aspects of glucose metabolism (intensity and configuration of uptake) whereas the radiologist reviewed aspects of morphology (diameters and intensity of the T2 signals). Thereby, the above-mentioned regions were classified as (a) involved = positive, (b) not involved = negative. The results were documented in separate SPSS tables (SPSS²⁴).

In a second step, both physicians reviewed discrepant findings jointly. For this purpose, diffusion weighted MR images were also reviewed whenever available. Consensus was reached by weighing the respective image information ([¹⁸F]-FDG, T2-TIRM coronal and transversal, diffusion-weighted images) and discussing them with other experienced colleagues.

Third, findings on [¹⁸F]-FDG-PET/MR images were correlated with the results of other clinical investigations or imaging modalities as mentioned above.

Results

Patient characteristics and results of performed investigations beyond whole-body [¹⁸F]-FDG-PET/MRI

Table 1 shows main patient characteristics and results of staging investigations aside from [¹⁸F]-FDG-PET/MRI parameters. Additionally, two of the 10 patients reported B symptoms. Lactate dehydrogenase (LDH), measured upon hospital admission, was highly normal to moderately elevated in most patients. Respective values ranged from 4 to 22 µkat/l (normal values: 1.94–4.78 µkat/l).

Two of the ten patients underwent chest CT ruling out micro-nodular involvement in both of them.

[¹⁸F]-FDG-PET/MRI data analysis

Lymph node regions

In 10 patients a total of 190 lymph node regions were evaluated. The results are displayed in Table 2. Altogether, four discrepancies between [¹⁸F]-FDG and MRI (T2-TIRM transversal, coronal) reading occurred (Table 2) and are described below. Decision making is summarized in Table 3.

Cervical neck (Fig. 1a–c, Table 3*) In this case, morphologically inconspicuous upper cervical lymph nodes (level II) were detectable on MRI on both sides of the upper neck (lymph node size/right side: 1.8 × 1.6 × 1.2 cm; lymph node size/left side: 1.9 × 1.8 × 0.8 cm) (Fig. 1a), which is not uncommon in children. However, for the lymph nodes on the right side, in contrast to the other side, moderate to markedly increased glucose metabolism was detectable (SUVₘₐₓ right side: 3.96; SUVₘₐₓ left side: 1.84), making these lymph nodes suspicious for lymphoma involvement (Fig. 1b). This was supported by diffusion restriction of the right sided lymph nodes only (ADC right on average: 643 × 10⁻⁶ mm²/s versus ADC left on average: 1480 × 10⁻⁶ mm²/s) (Fig. 1c). In conclusion, the lymph nodes on the right side of the upper neck were determined to be most likely involved.

Axillary lymph nodes on the right and left side (Fig. 2a–e, Table 3**) This patient presented with enlarged cervical lymph nodes in levels II, III and IV on both sides of the neck (Fig. 2a). In addition, there were numerous small (<1 cm) lymph nodes continuously extending from the cervical level II into both axillae (Fig. 2a). These small nodes were embedded in fatty tissue, which exhibited a pathologic signal on T2-TIRM sequences (Fig. 2a+b). However, the small bilateral axillary lymph nodes did not show increased glucose metabolism (SUVₘₐₓ right side: 1.17; SUVₘₐₓ left side: 1.25) (Fig. 2c+d). Furthermore, diffusion was not restricted (ADC right: 1693 × 10⁻⁶ mm²/s; ADC left: 1746 × 10⁻⁶ mm²/s) (Fig. 2e).

Taken all information together (lymph nodes <1 cm, no increased glucose metabolism, no diffusion restriction) it was decided to consider both axillae not to be involved.

Lung hilum (Fig. 3a–c, Table 3***) Hilar lymph nodes are often affected, especially during respiratory tract inflammation and therefore may show moderately to markedly increased glucose metabolism as in this case (SUVₘₐₓ 3.3) (Fig. 3a). However, neither patient history and clinical investigation nor whole-body [¹⁸F]-FDG-PET/MRI gave evidence of any active respiratory tract inflammation. Thus, an increased glucose metabolism of the left hilum lymph node was determined suspicious of lymphoma. However, on MRI the left hilar lymph node was small
(0.9 × 0.7 cm) and diffusion was not restricted (ADC: $3800 \times 10^{-6}$ mm$^2$/s) (Fig. 3b+c).

This information combined (i.e., moderately increased glucose metabolism, but small lymph node and no diffusion restriction), the region was determined not involved.

### Table 2  Lymph node regions separated by imaging modality

| Lymph node region       | Evaluation of MR | Evaluation of PET | Consensus (MR + PET) |
|-------------------------|------------------|-------------------|----------------------|
|                         | Negative | Positive | Negative | Positive | Negative | Positive |
| Right upper neck*       | 6/10     | 4/10     | 5/10     | 5/10     | 5/10     | 5/10     |
| Left upper neck         | 6/10     | 4/10     | 6/10     | 4/10     | 6/10     | 4/10     |
| Right lower neck        | 6/10     | 4/10     | 6/10     | 4/10     | 6/10     | 4/10     |
| Left lower neck         | 8/10     | 2/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Right clavicular        | 6/10     | 4/10     | 6/10     | 4/10     | 6/10     | 4/10     |
| Left clavicular         | 7/10     | 3/10     | 7/10     | 3/10     | 7/10     | 3/10     |
| Right axillary**        | 7/10     | 3/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Left axillary**         | 7/10     | 3/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Right lung hilum        | 8/10     | 2/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Left lung hilum***      | 9/10     | 1/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Mediastinum             | 6/10     | 4/10     | 6/10     | 4/10     | 6/10     | 4/10     |
| Splenic hilum           | 10/10    | 0/10     | 10/10    | 0/10     | 10/10    | 0/10     |
| Liver hilum             | 10/10    | 0/10     | 10/10    | 0/10     | 10/10    | 0/10     |
| Mesenterial             | 8/10     | 2/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Paraaortic              | 6/10     | 4/10     | 6/10     | 4/10     | 6/10     | 4/10     |
| Right ili cal            | 8/10     | 2/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Left ili cal             | 7/10     | 3/10     | 7/10     | 3/10     | 7/10     | 3/10     |
| Inguinal re              | 8/10     | 2/10     | 8/10     | 2/10     | 8/10     | 2/10     |
| Inguinal li              | 9/10     | 1/10     | 9/10     | 1/10     | 9/10     | 1/10     |
| Sum                     | 142/190  | 48/190   | 142/190  | 48/190   | 142/190  | 48/190   |

* discrepancy during first lymph node evaluation in the right upper neck
** discrepancy during first lymph node evaluation in the right and left axillary
*** discrepancy during first lymph node evaluation left lung hilum

### Table 3  Summary of the decision-making process in case of discrepancies between 18F-FDG-PET and MR concerning lymph node staging

| Case (Figure) | 1* | 2** | 3*** |
|---------------|----|-----|------|
| 18F-FDG-PET   | ++ | –   | +    |
| MR (TIRM cor/trans) | –  | (+) | –    |
| ADC           | +  | –   | –    |
| Final decision| +  | –   | –    |

* discrepancy during first lymph node evaluation in the right upper neck
** discrepancy during first lymph node evaluation in the right and left axillary
*** discrepancy during first lymph node evaluation left lung hilum
–not involved, (+) possibly involved, ++/+/+ involved

### Central nervous system (CNS)

None of the ten patients had CNS involvement according to cerebrospinal fluid (CSF) cytology. Correspondingly, [18F]-FDG-PET/MRI images were completely inconspicuous.

### Waldeyer’s ring (WR)

ENT exam performed by pediatric oncologists is a common way to decide on WR involvement [6].

WR involvement was suspected by ENT exam in two of our patients. However, the region appeared inconspicuous both on MRI and [18F]-FDG-PET (Table 1). On the other hand, there were two patients with negative ENT exam who both unequivocally were identified to have WR involvement on [18F]-FDG-PET and MR images (Table 1).

In Fig. 4 the images of one patient with negative ENT exam but diagnosis of WR involvement according to [18F]-FDG-PET/MRI are shown: The nasopharyngeal
level (Fig. 4c+d) appears enlarged and the pharyngeal tonsil is configured irregularly (Fig. 4c+d). Glucose metabolism is markedly increased and distributed asymmetrically (SUV\(_{\text{max}}\) right: 14.36; SUV\(_{\text{max}}\) left: 11.31) (Fig. 4a+b).

**Lungs**
None of the ten patients had suspicion of lung involvement on \[^{18}\text{F}\]-FDG-PET/MRI images, which was confirmed at least in two patients by additional chest CT.

**Pleura**
Four out of ten patients had pleural effusion without evidence of nodular pleural thickening on T2-TIRM images.
However, on $[^{18}F]$-FDG-PET images, two of them showed an area of increased glucose metabolism along the parietal pleura.

$[^{18}F]$-FDG-PET/MRI images from one of those two patients are displayed in Fig. 5: Corresponding to increased glucose metabolism in an area of the left posterior pleura ($S_{UV,max}$ left: 2.88; $S_{UV,max}$ right: 0.86) (Fig. 5a, c, f, h), diffusion was restricted in this area as well (ADC levels of about $636 \times 10^{-6}$ mm$^2$/s) (Fig. 5d+e). In keeping with this, malignant cells (96%) were detected during thoracentesis (Table 1). However, distinction between pleural effusion and lymphoma manifestation of the pleura remained impossible on MRI T2-TIRM images, also on re-evaluation (Fig. 5b+g).

**Spleen**

In concordance with ultrasound, splenic parenchyma of all ten patients was inconspicuous both morphologically (i.e., no focal lesions detectable on MRI) and metabolically (i.e., tracer uptake of the spleen $<$ tracer uptake of the liver and/or the BM). However, in one patient ultrasound and MRI concluded splenomegaly.

**Liver**

None of the ten patients had suspicion of liver involvement on $[^{18}F]$-FDG-PET/MRI which was in accordance with ultrasound.

**Kidneys**

Ultrasound as well as MRI and $[^{18}F]$-FDG-PET concordantly identified two patients with bilateral lymphoma manifestations of the kidneys.

Figure 6 shows imaging from one of the two patients: $[^{18}F]$-FDG-PET reveals multiple areas of markedly increased glucose uptake ($S_{UV,max}$ right kidney: 38.02; $S_{UV,max}$ left kidney: 42.91; $S_{UV,max}$ bladder: 12.8 for comparison) in both organs (Fig. 6a–c). On T2-TIRM images, the involved kidneys appear enlarged with blurring of the corticomedullary junctions (Fig. 6d). ADC values on DWI reached near-pathologic values at about $908 \times 10^{-6}$ mm$^2$/s (Fig. 6e).

**Skeleton**

Six of the ten patients were identified to have skeletal involvement (one DLBCL, two primary osseous NHL, one Burkitt lymphoma, two T-cell lymphoma). In five patients, only $[^{18}F]$-FDG-PET/MRI was indicative of involvement. In one patient, both $[^{18}F]$-FDG-PET/MRI and bone marrow (BM) biopsy showed involvement.

In the six patients, a total of 13 skeletal lesions were detected on $[^{18}F]$-FDG-PET/MRI. These comprised six lesions accompanied by local bone destruction, and seven lesions confined to BM exclusively. All six lesions with local bone destruction were detected on $[^{18}F]$-FDG-PET and MRI during the first run. Two of the seven lesions confined to BM were first missed on MRI analysis. However, after knowing the localization of increased glucose metabolism, correlating very small lesions could be identified on MRI (on TIRM sequences and on DWI) (Fig. 7).

The patient in whom BM biopsy was positive had extended lymphoma involvement of the left pelvic bones and the needle track ran directly through the lymphoma manifestation (Fig. 8i–l).

Pertaining to the five patients whose BM biopsy was negative despite of skeletal lymphoma involvement it is noteworthy that one focal skeletal lesion was not far (approximately 4.2 cm) located from the biopsy site (Fig. 8a–h).

**Discussion**

A new staging system for pediatric NHL was released in 2015 [2]. The respective publication also mentions the developments of cross-sectional imaging over the past decades including the latest which is $[^{18}F]$-FDG-PET/MRI [2]. We performed a single-center evaluation with ten pediatric NHL patients at the time of initial diagnosis in order to investigate the performance of $[^{18}F]$-FDG-PET/MRI by using a limited number of MRI
sequences. A focus was put on lymph node regions as well as organs and several extranodal sites of potential lymphoma involvement.

To date publications evaluating the application of $[^{18}F]$-FDG-PET and MRI (including DWI) in NHL patients stem from imaging procedures performed separately of each other. Thereby, time intervals of up to two weeks are described [7–9]. However, during such time intervals lymphoma may have further developed and spread. Furthermore, other non-malignant diseases like tonsillitis or pneumonia may occur or resolve in the meantime and could lead to differing results. In this respect, a comparison is not valid. In contrast to that, simultaneous $[^{18}F]$-FDG-PET/MRI allows
imaging without any delay between the two modalities and therefore a more reliable comparison of the respective findings.

In our evaluation, a total of 190 lymph node regions were assessed. For 186 of 190 (98%), [18F]-FDG-PET and MRI came to concordant results. This is in line with the literature describing high [18F]-FDG-PET avidity for most lymphoma subtypes and excellent lymph node accessibility with whole-body MRI [10–12]. For the few cases with discrepant findings the addition of diffusion weighted images (DWI) facilitated decision making. Using the cutoff value at $800 \times 10^{-6}$ mm$^2$/s for non-Hodgkin lymphoma, which was also suggested by Kwee et al. [13] and Vermolen et al. [14], resulted in a clear differentiation.

Fig. 5  
(a–h) [18F]-FDG-PET images transversal and coronal (a, f), MR T2-TIRM images transversal and coronal (b, g), [18F]-FDG-PET/MRI (c, h) and DWI at b-value of 800 (d, e) of the thorax. The blue arrows point to an area of the left posterior pleura with increased glucose uptake (SUV$_{max}$ 2.88) (a, c, f, h) and a restriction in diffusion (ADC levels of about $636 \times 10^{-6}$ mm$^2$/s) (d, e). This area corresponds to pleura involvement which is not distinguishable from pleural effusion on MR T2-TIRM images (b, g)
between likely and unlikely lymphoma involvement. We were aware that motion artifacts, which often occur in the areas of neck, chest and abdomen, may impair the reliability of DWI and ADC values [15]. In our limited cohort, however, such problems were not noticed which may be due to the increased efforts in handling pediatric patients (e.g., sufficient immobilization during [18F]-FDG-PET/MRI acquisition or the use of respiratory triggering) [3]. Thus, further evaluation of the potential capacity of DWI seems warranted in order to establish this functional information as a third cornerstone beside morphology and metabolism.

The Waldeyer’s ring (WR) turned out to be a region with noticeable discrepancies between clinical examination and [18F]-FDG-PET/MRI: In two patients, suspicion of WR involvement based on ENT exam could not be confirmed on [18F]-FDG-PET/MR images. On the other hand, there were two patients showing highly suspicious pattern of their WR on [18F]-FDG-PET/MRI with unremarkable ENT exam. Those discrepancies can result from different facts: First, ENT exam as an inspection of the oral cavity, regularly performed by pediatric oncologists, can only evaluate the oro-pharynx. The nasopharynx (e.g., pharyngeal tonsil) remains unevaluated if not examined by an ENT specialist, only the mucosal surface is evaluated but not the underlying tissue. Furthermore, alterations of the mucosa can be unspecific and therefore difficult to interpret. This makes ENT examinations highly subjective and therefore prone to interobserver variability [6, 16]. Thus, an evaluation of the WR should always include cross-sectional imaging, preferably [18F]-FDG-PET/MRI. The detection of WR involvement is crucial to anticipate airway obstruction early on especially in patients with NHL entities often affecting the WR such as Burkitt lymphoma and DLBCL [16, 17]. Furthermore, there is evidence that NHL patients with WR involvement may benefit from irradiation of their WR [18, 19].

Concerning pleura involvement, the results of our study support previous assumptions that [18F]-FDG-PET can differentiate between pleural effusion and malignant pleura involvement [20]. Pleural assessment, however, is challenging on whole-body MR sequences, especially if solely coronal slices are acquired [21, 22]: Due to the thoracic convexity, coronal slices are prone to partial volume effects. Partial volume effects considerable complicate the assessment of the pleura, so that small lesions in particular are easily missed. On transversal slices, by contrast, partial volume effects are less frequent, making them more suitable for pleural assessment. Another option would be a dedicated lung MRI. However, this
would significantly prolong imaging time and contra-
dicts the intention of whole-body MRI which is to pro-
vide a fast overview without loss of compliance in young
patients due to long imaging time.

Splenic involvement occurs in about 30–40% of all
NHL patients [23]. However, in the cohort analyzed here,
none of the patients had suspicious focal lesions within
splenic parenchyma, neither on ultrasound nor on MRI
or $^{[18]}$F-FDG-PET. Nevertheless, in one patient sple-
nomegaly was detectable. Splenomegaly is challenging
because it is a relatively unspecific sign. It can accompany
spleen involvement as well as various pathologies like
infectious diseases (e.g., mononucleosis, malaria), meta-
bolic disorders (e.g., Morbus Gaucher) or liver diseases
resulting in portal hypertension [24]. In case of normal
parenchymal texture some publications suggest com-
paring radiotracer uptake of the spleen with liver and/
or bone marrow uptake. If tracer uptake of the spleen
exceeds tracer uptake of liver and/or bone marrow, it is
recommended to assume spleen involvement [25, 26]. In
our patient with splenomegaly on ultrasound, radiotracer
uptake of the spleen did not exceed that of the liver or the
bone marrow.

Kidney involvement was detected in two of the ten
patients. Both patients had bilateral renomegaly due to
extensive lymphoma infiltration. In young NHL patients
with kidney involvement, multiple bilateral large lesions
are the most commonly found pattern [27, 28]. Both MRI
(including DWI) and $^{[18]}$F-FDG-PET were able to cor-
rectly detect kidney involvement. This is important to
mention for $^{[18]}$F-FDG-PET, since kidney evaluation with
$^{[18]}$F-FDG-PET is often regarded as extremely challeng-
ing due to renal excretion of the radiotracer. However,
cortical lesions and manifestations distant from the col-
lecting system are well distinguishable from physiological
tracer excretion as it was in our two patients.

Skeletal involvement in NHL patients can be either
focal or diffuse. Literature review suggests a pattern
of rather focal involvement in patients with DLBCL,
whereas other NHL entities tend toward diffuse bone marrow infiltration [29–31].

Bone marrow biopsy is much more sensitive in detecting diffuse BM infiltration compared to [18F]-FDG-PET and MRI [32–35]. In contrast, a focal involvement pattern is detectable on [18F]-FDG-PET and MR images with the highest sensitivity [32–34]. All six patients from our cohort who had skeletal involvement (only one of them had DLBCL) exhibited a pattern of focal involvement which was well detectable through [18F]-FDG-PET/MRI. However, BM biopsy taken from the iliac crest was negative in five out of the six cases. It is worth mentioning that BM biopsy was also negative in the patient in whom one of the BM lesions was not far located from the needle track. This suggests that BM biopsy probably only yields a positive result if the biopsy needle hits the lesion visible on imaging, which, in turn, may explain the low sensitivity of bone marrow biopsies in case of a focal involvement pattern.

In one of the six patients [18F]-FDG-PET/MRI and BM biopsy were positive. This constellation could be of prognostic value: Based on an analysis of 327 adult DLBCL patients, Cerci et al. [36] found that patients who were positive in both modalities, [18F]-FDG-PET and BM biopsy, had a worse outcome compared to patients who were positive in only one modality. However, in our patient the needle track ran directly through the lymphoma manifestation. Thus, in this patient positivity of both modalities does not necessarily imply a worse outcome.

Several limitations of this retrospective evaluation need to be mentioned:

First, the number of cases is small. Thus, the described results should be confirmed, preferably within a large multicenter trial with predefined image acquisition parameters.

Second, the investigated cohort does not cover the typical spectrum of childhood NHL entities, which are Burkitt lymphoma, lymphoblastic lymphoma and anaplastic large-cell lymphoma. The spectrum of this study refers to an adolescent population in which DLBCL is more common.

Third, our study population does not seem to include high-risk patients. Particularly LDH, as one of the main risk factors, was relatively low in all cases.
Forth, some of the potential sites of extranodal NHL involvement like CNS, liver and lung were not evident in the analyzed cohort, precluding the assessment of the full potential of [18F]-FDG-PET/MRI imaging.

Fifth, despite being able to show that the applied DWI performed excellent, it has to be mentioned that new developments concerning DWI have evolved, e.g., whole-body-DWI with background suppression (DWIBS) [37]. The latter provides superior local resolution and reduced artifact susceptibility [38]. It is characterized by a relatively short acquisition time, which is particularly desirable in the setting of whole-body imaging in children and adolescents [39]. And a robust fat suppression has a positive effect on subsequent three-dimensional reconstruction. In young children, however, the physiological diffusion restriction of the pelvis and spine has to be taken into account, since it could lead to false positive findings [39]. New opportunities to display DWI findings (e.g., MIP grey-scale inverted DWI) might also facilitate direct comparison between function and metabolism.

Sixth, the clinical and paraclinical results were used as standard of reference to some of the imaging results. However, clinical and paraclinical parameters have limitations as well. To overcome these limitations, confirmation through biopsy would be necessary. The latter, however, is often not feasible nor justifiable in the clinical setting as well as ethically.

Seventh, the aim of this study was to evaluate the performance of whole-body [18F]-FDG-PET/MRI for a limited overall acquisition time. It was not the aim to compare [18F]-FDG-PET and MRI. For that, a broader spectrum of MRI sequences would have been necessary leading to a considerable prolongation of image acquisition time, which is difficult in a pediatric age group. However, imaging technology is developing quickly. Thus, in the future a broader spectrum of MR sequences can be expected to be acquired within one hour of acquisition time.

Conclusion
Despite the small cohort investigated here, we were able to show that whole-body [18F]-FDG-PET/MR is a valuable staging tool in pediatric NHL, especially when it comes to the evaluation of the skeleton, the Waldeyer’s ring, pleura and lymph nodes. Thereby, morphologic, metabolic and functional (DWI) information complement each other well.

Abbreviations
ADC: Apparent diffusion coefficient; BM: Bone marrow; CNS: Central nervous system; CT: Computed tomography; DLBCL: Diffuse large B-cell lymphoma; DWI: Diffusion weighted images; DWIBS: DWI with background suppression; EANM: European association of nuclear medicine and molecular imaging; ENT: Ear, nose, throat; [18F]-FDG-PET/CT: 2-Deoxy-2-[18F]fluoro-o-glucose positron emission tomography/computed tomography; [18F]-FDG-PET/MRI: 2-Deoxy-2-[18F]fluoro-o-glucose positron emission tomography/magnetic resonance imaging; HL: Hodgkin lymphoma; IPNHSSL: International pediatric non-Hodgkin lymphoma staging system; LDH: Lactate dehydrogenase; NHL: Non-Hodgkin lymphoma; TIRM: Turbo-inversion recovery magnitude; WR: Waldeyer’s ring.

Acknowledgements
We would especially like to thank our technologists—Cornelia Pötzsch, Tanja Winkler, Tanja Uhlish, Katja Römull, Martin Weberh and Torsten Bohn— who mainly contributed to a smooth performance of [18F]-FDG-PET/MRI investigations in children.

Authors’ contributions
LK and CR contributed to conception and design, data analysis and drafting. LK, RK, OS, LF, SW, HGE, SS, J-SK, YC, FWH, IS and CR contributed to data interpretation, revision and final approval. CR, LK, IS, FWH, RK and OS contributed to visualization. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
The datasets generated and analyzed during the current study (SPSS tables) are available from the corresponding authors upon request.

Declarations
Ethical approval
The Ethics Committee of the Medical Faculty of the University of Leipzig approved the evaluation presented here. The Ethics Committee is registered as Institutional Review Board (IRB) at the Office for Human Research Protections (OHRP). The registration number is as follows: IORG0001320, IRB00001750.

Consent to participate
Written informed consent was obtained from all patients and/or their legal guardians for scientific evaluation of their data before inclusion into this retrospective analysis.

Competing interests
None of the authors has any competing interest.

Author details
1Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; 2Department of Pediatric Oncology, Hematology and Hemostaseology, University Hospital Leipzig, Leipzig, Germany; 3Institute of Pediatric Radiology, University Hospital Leipzig, Leipzig, Germany.

Received: 5 February 2021   Accepted: 10 June 2021
Published online: 03 July 2021

References
1. McCarten KM, Nadel HR, Shulkin BL, et al. Imaging for diagnosis, staging, response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol. 2019;49:1545–64.
2. Rosolen A, Perkin S, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system. JCO. 2015;33:2112–8.
3. Hirsch FW, Sattler B, Sorge I, et al. PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013;43:860–75.
4. EANM pediatric dosage calculator. https://www.eanm.org/publications/dosage-calculator. Accessed 29 July 2020.
5. Kluge R, Kurch L, Georig T, et al. Current role of FDG-PET in pediatric Hodgkin’s lymphoma. Semin Nucl Med. 2017;47:242–57.
6. Seelisch J, de Alarcon PA, Flerlage JE, et al. Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: the staging, evaluation, and response criteria harmonization (SEARCH) for children, adolescent, and young adult Hodgkin lymphoma (CAHLP) group. Pediatr Blood Cancer. 2020;77:e28361. https://doi.org/10.1002/pbc.28361.

7. Quaresmes V, Furlong HW, Kwee TC, Beek EJ, et al. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR. 2011;196:662–9.

8. Litojoo AS, Kwee TC, Barber I, et al. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT based reference standard. Eur Radiol. 2014;24:1153–65.

9. Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging in lymphoma. Cancer Imaging. 2010;20:1572–8. https://doi.org/10.1102/1470-7330.2010.9029.

10. Weiler-Sagie M, Bushelev O, Epelbaum O, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. JNM. 2010;51:25–30.

11. van den Brekel MW, Castelijns JA. Imaging of lymph nodes in the neck. Semin Roentgenol. 2000;35:42–53.

12. Suh CH, Choi YJ, Baek JH, Lee JH. The diagnostic value of diffusion-weighted imaging in differentiating metastatic lymph nodes of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Am J Neuroradiol. 2018;39:1889–95.

13. Kwee TC, Ludwig I, Uiterwaal CS, et al. ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. Magn Reson Mater Phys. 2011;24:1–8.

14. Vermoelen MA, Kwee TC, Nieveldstein AJ. Apparent diffusion coefficient measurements in the differentiation between benign and malignant lesions: a systematic review. Insights Imaging. 2012;3:395–409.

15. Mayerhofer ME, Karkanas G, Kletter K, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res. 2014;20:2984–93.

16. Guimaraes AC, de Carvalho GM, Bento LR, et al. Clinical manifestation in children with tonsillar lymphoma: a systematic review. Crit Rev Oncol Hematol. 2014;90:146–51.

17. Chen L, Al-Kazayer LFY, Li Y, Lui T. B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients. Oncotarget. 2017;8:11544–54.

18. Laskar S, Bahl G, Muckaden MA, et al. Non-Hodgkin's lymphoma of Waldeyer’s ring in children: outcome using chemotherapy and involved field radiotherapy. Clin Oncol. 2006;20:613–8.

19. Han AY, Kuan EC, Alonso IE, Badran KW, John MAS. Epidemiology of nasopharyngeal lymphoma in the United States: a population-based analysis of 1119 cases. Otalaryngol Head Neck Surg. 2017;156:870–6.

20. McCarten KM, Metzger ML, Drachman RA, et al. Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: report from Children's Oncology Group protocol AHO0031. Pediatr Radiol. 2018;48:1736–44.

21. Kwee TC, Vermoelen MA, Akkerman EA, et al. Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J Magn Reson Imaging. 2014;40:26–36.

22. Krohmer S, Jorje I, Krausse A, et al. Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol. 2010;74:256–61.

23. Saboo SS, Krajewski KM, O'regan KN, et al. Imaging of the spleen: spectrum of abnormalities. Radiographics. 2005;25:967–82.